Trading update

Hikma Pharmaceuticals Plc
24 October 2006



                     Hikma Pharmaceuticals - Trading update

LONDON, 24 October 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), the
multinational pharmaceuticals group, is today updating the market on the Group's
current trading performance.

Our Branded and Injectables businesses continue to perform well and it is
expected that both will deliver strong growth for the full year. However, in the
Generic business we have seen decreasing wholesaler inventories and a lower than
forecast contribution from new product launches. It is therefore now expected
that full year Generic sales will be slightly below those achieved in 2005.

The Group will issue a further update prior to entering its close period in
January 2007.

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC
Susan Ringdal                                          [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed               [phone]


About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange